滚动资讯
FierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic targetFierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerFierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapyFierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from AsiaFierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reportsLonza NewsSimulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocusLonza NewsSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.comLonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.comBioWorldJapanese researchers report new μ-opioid receptor antagonistsBioWorldIncyte discloses new TYK2 and/or JAK1 inhibitorsBioWorldInsilico Medicine divulges new NLRP3 inflammasome inhibitorsBioWorldNeolaia synthesizes new CD38 inhibitors
Waters 2025年11月27日

Công ty Waters Corporation có phải là cổ phiếu hấp dẫn cho danh mục hưu trí - Giao dịch nội bộ và ý tưởng tăng trưởng vốn an toàn - BỘ NỘI VỤ

Công ty Waters Corporation có phải là cổ phiếu hấp dẫn cho danh mục hưu trí - Giao dịch nội bộ và ý tưởng tăng trưởng vốn an toàn - BỘ NỘI VỤ

原文
暂时没有全文，请查看原始来源。